Literature DB >> 26346349

Vasculitic Neuropathies.

Elie Naddaf1, P James Bonham Dyck.   

Abstract

OPINION STATEMENT: From pathological standpoint, we divide vasculitic neuropathies in two categories: nerve large arteriole vasculitides and nerve microvasculitis. It is also important to determine whether a large arteriole vasculitis has an infectious etiology as it entails different treatment approach. Treatment of non-infectious large arteriole vasculitides consists initially of induction therapy with corticosteroids. Adding an immunosuppressant, mainly cyclophosphamide, is often needed. Treatment of infectious large arteriole vasculitides needs a multidisciplinary approach to target both the underlying infection and the vasculitis. Corticosteroids are the first-line therapy for classic non-systemic vasculitic neuropathy. Stable or improving patients without biopsy evidence of active vasculitis can be either observed or treated. Currently, adding an immunosuppressant is only indicated for patients who continue to progress on corticosteroids alone or patients with a rapidly progressive course. The treatment of the radiculoplexus neuropathies such as diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy (in non-diabetic patients), and diabetic cervical radiculoplexus neuropathy, as well as painless diabetic motor neuropathy, is not well established yet. We treat patients, if they present early on in the disease course or if they have severe disabling symptoms, with IV methylprednisolone 1 g once a week for 12 weeks.

Entities:  

Year:  2015        PMID: 26346349     DOI: 10.1007/s11940-015-0374-1

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  105 in total

1.  Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Authors:  Rodrigo Cartin-Ceba; Jason M Golbin; Karina A Keogh; Tobias Peikert; Marta Sánchez-Menéndez; Steven R Ytterberg; Fernando C Fervenza; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2012-11

2.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.

Authors:  D R Jayne; H Chapel; D Adu; S Misbah; D O'Donoghue; D Scott; C M Lockwood
Journal:  QJM       Date:  2000-07

Review 3.  Vasculitic neuropathies.

Authors:  Kelly Graham Gwathmey; Ted Michael Burns; Michael Paul Collins; P James Bonham Dyck
Journal:  Lancet Neurol       Date:  2014-01       Impact factor: 44.182

4.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Authors:  L Guillevin; J F Cordier; F Lhote; P Cohen; B Jarrousse; I Royer; P Lesavre; C Jacquot; P Bindi; P Bielefeld; J F Desson; F Détrée; A Dubois; E Hachulla; B Hoen; D Jacomy; C Seigneuric; D Lauque; M Stern; M Longy-Boursier
Journal:  Arthritis Rheum       Date:  1997-12

5.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

6.  Peripheral neuropathy in primary Sjögren's syndrome.

Authors:  S I Mellgren; D L Conn; J C Stevens; P J Dyck
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

7.  Methylprednisolone may improve lumbosacral radiculoplexus neuropathy.

Authors:  P J Dyck; J E Norell; P J Dyck
Journal:  Can J Neurol Sci       Date:  2001-08       Impact factor: 2.104

8.  Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy.

Authors:  Stefano Tamburin; Giampietro Zanette
Journal:  Pain Med       Date:  2009-09-25       Impact factor: 3.750

9.  Azathioprine toxicity in neuromuscular disease.

Authors:  J T Kissel; R J Levy; J R Mendell; R C Griggs
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

10.  Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  E M Miloslavsky; U Specks; P A Merkel; P Seo; R Spiera; C A Langford; G S Hoffman; C G M Kallenberg; E W St Clair; N K Tchao; L Viviano; L Ding; L P Sejismundo; K Mieras; D Iklé; B Jepson; M Mueller; P Brunetta; N B Allen; F C Fervenza; D Geetha; K Keogh; E Y Kissin; P A Monach; T Peikert; C Stegeman; S R Ytterberg; J H Stone
Journal:  Arthritis Rheum       Date:  2013-09
View more
  1 in total

Review 1.  Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases.

Authors:  Delia Tulbă; Bogdan Ovidiu Popescu; Emilia Manole; Cristian Băicuș
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.